In vivo experiments demonstrate that patients resistant to docetaxel/cisplatin/5-fluorouracil (TPF) have the upregulation of c-Jun in their hypopharyngeal carcinoma tissues (21), while overexpression of c-Jun inhibits human hepatoma cells from being sensitive to sorafenib during treatment (22). This evidence concerns the gene JUN and hepatocellular carcinoma.